中央研究院智財技轉處對外服務網

Neuroblastoma (NB) is a common childhood tumor derived from primitive sympathetic neuroblasts and accounts for 15% of pediatric cancer deaths. Although current risk stratification is useful for selection of appropriate therapeutic regimens, there is still a lack of useful markers for predicting treatment failure in lower risk patients and high risk patients. The invention relates to progmostic markers specific for neuroblastoma that can predict tumor behavior and refine risk assessment in a patient diagnosed with neuroblastoma, and more particularly to methods for delineating neuroblastoma patients into clinical risk groups by observing MicroRNA signature and expression of Dicer and Drosha.